

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 8, 2018**

OrthoPediatrics Corp.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-38242

(Commission File Number)

26-1761833

(I.R.S. Employer Identification Number)

**2850 Frontier Drive
Warsaw, Indiana**

(Address of principal executive offices)

46582

(Zip Code)

Registrant's telephone number, including area code: **(574) 268-6379**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Item 7.01. Regulation FD Disclosure.

The executive officers of OrthoPediatics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.1 herewith, in whole or in part, as part of those presentations.

The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	OrthoPediatics Corp. Investor Presentation dated January 2018.

* * * * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OrthoPediatrics Corp.

Date: January 8, 2018

By: /s/ Daniel J. Gerritzen
Daniel J. Gerritzen,
General Counsel and Secretary



OrthoPediatrics Corp.
January 2018

Mark Throdahl, CEO
Fred Hite, CFO



This presentation contains and related discussion may contain “forward-looking statements” within the meaning of U.S. federal securities laws. All statements contained in this presentation and related discussion other than statements of historical facts are forward-looking statements. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plans and strategies. You can identify forward-looking statements by the use of words such as “may,” “might,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “intend,” “future,” “potential,” “suggest,” “target,” “forecast,” “continue” and other similar expressions. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs, estimates, projections and various assumptions, many of which are inherently uncertain and beyond our control. Such expectations, beliefs, estimates, projections and assumptions are expressed in good faith and management believes there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, estimates, projections and assumptions will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements, including risks detailed in the most recently filed Quarterly Report on Form 10-Q for the period ended September 30, 2017 filed by OrthoPediatrics Corp. (the “Company”) with the U.S. Securities and Exchange Commission (the “SEC”) on November 13, 2017. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances or other changes affecting forward-looking information except to the extent required by applicable securities laws. Certain information in this presentation is based upon management forecasts and reflects prevailing conditions and management’s views as of this date, all of which are subject to change.

Before you invest, you should read the most recently filed Quarterly Report on Form 10-Q and other documents the Company has filed and will file with the SEC for more complete information about the Company. You may obtain these documents for free by visiting EDGAR on the SEC website at <http://www.sec.gov>.

The Company owns or has rights to use a number of registered and common law trademarks, service marks and trade names in connection with its business in the United States and in certain foreign jurisdictions, including the OrthoPediatrics name and logo. Solely for convenience, the trademarks, service marks and trade names referred to in this presentation may be without the ® and ™ symbols, but such references are not intended to indicate, in any way, that the Company will not assert, to the fullest extent under applicable law, its rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This presentation contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this presentation are, to the Company’s knowledge, the property of their respective owners.



Large Market

Proprietary Technology

Scalable Business

- 👤 **Orthopedic company focused exclusively on pediatric orthopedics**
- 👤 **Protected market opportunity: \$1.1 billion U.S., \$2.5 billion globally in 2016**
- 👤 **High U.S. procedure concentration: <300 hospitals and ~1,200 surgeons**
- 👤 **Focused call point: generalists who use our entire product portfolio**
- 👤 **Broadest product offering: 24 systems specifically designed for children**
- 👤 **Sustainable competitive advantage:**
 - Comprehensive product offering
 - Clinical education programs
 - Surgeon relationships
 - Experienced sales organization
- 👤 **FY17E revenue of \$45.4M-\$45.6M, which represents ~22% revenue growth**
- 👤 **Recent IPO will, among other things, fund consigned sets and accelerate proven strategy**



A Company Built on a CAUSE

Cause

Improving the lives of children with orthopedic conditions



Gideon with CMO Peter Armstrong, M.D., c. 1995.
Gideon's drawing of his girlfriend, 2016.

Company Snapshot*

- Treated **16,000** patients in 2016
- 24** surgical systems; **2,700** SKUs; strong pipeline
- 62** direct employees; **69** focused FTE sales reps
- Global** sales organization focused on pediatric orthopedic surgeons in **36** countries
- International**: **31** stocking distributors; **2** sales agencies
- 21** issued patents; **19** pending patents
- Only non-founding Chief Medical Officer in the industry who is a fellow surgeon**
- Average FDA approval time: < ½ industry average**
- History of stable reimbursement**

* As of Q3 2017 (with the exception of surgical systems as KIDS launched two products following Q3)



Children Are Not Small Adults

Superior Clinical Outcomes

Re-Purposed Adult Plate



Screws Through Growth Plate

OP's Solution



Screws Parallel To Growth Plate


OP's Market Impact

- 🔍 **Address orthopedic industry's lack of focus** on product development, clinical education, and sales presence
- 🔍 **Implants and instruments** avoid complications of re-purposed adult products
- 🔍 **Product development** in collaboration with leading pediatric orthopedic surgeons
- 🔍 **Dedicated sales support** attending surgeries
- 🔍 **Clinical education** programs that build brand loyalty




OP'S \$2.5 Billion Current Addressable Global Market

\$1.1 Billion U.S. Addressable Market



High Concentration of Pediatric Trauma & Deformity and Complex Spine Procedures




**Current products target three of the largest categories in Pediatric Orthopedics
Pipeline products underway to expand addressable market**




Product Line Diversification

2016 Revenue by Segment




- \$37 million sales in 2016
- 20% revenue growth in 2016
- No dependency on one product family
- Consistent growth across all products
- Comparable gross margins on all products

2016 Revenue by Product Family



2016 Revenue Growth % by Product Family





**Sales Focus
On Teaching
Institutions and
High Volume
Hospitals**

**Deploy
Instrument
Sets**

**Expand
Addressable
Procedures**

**Expand Clinical
Training
Programs**

Goals

-  **Accelerate sales growth (requires consigned sets)**
-  **Develop novel technologies**



Complex Spine

FIREFLY® Pedicle Screw Navigation Guides

OP has exclusive distribution rights in U.S. pediatric hospitals



Unique, patient-specific custom guide for screw placement

Provides a 3D printed, patient-specific guide for each vertebral level

Improves screw placement accuracy without the need for an expensive navigation or robotic system.

Eliminates intraoperative radiation and is ideally suited for large construct cases.

Complementary to our RESPONSE Spine System



Trauma & Deformity

Clavicle Plate System

*First clavicle system for pediatric patients
Based on proprietary access to Hamann-Todd Collection
Available in 2.7mm and 3.5mm sizes and
in 6, 7, and 8-hole versions*



Wrist Fusion Plate System

*First pediatric specific plates
Two implant lengths to accommodate patients with and
without proximal row carpectomy*

Titanium PediPlates® System

*Expands comprehensive physal tethering offering
Includes both O-Plates and I-Plates with solid and
cannulated low-profile screws*








Sports Medicine


Medial Patella Femoral
Ligament Reconstruction System

Full range of instruments accommodate any technique
Bioabsorbable interference screws
Complements ACL Reconstruction System






Expanding Our Addressable Market



Demonstrated ability to expand portfolio to full array of pediatric surgeries

- OP Today
- OP Tomorrow
- Now Under Development





New Competitors Would Face Formidable Obstacles



"The ship has sailed."

- 👤 **Product breadth**
- 👤 **Surgeon relationships**
- 👤 **Sales and distribution network**
- 👤 **Clinical education programs**
- 👤 **Pediatric brand equity**
- 👤 **Reputation with pediatric orthopedic societies**
- 👤 **Dynamic culture**




What Does Category Leadership Mean?

Surgeon relationships and Clinical education

- Relationships with surgeons who use entire portfolio
- Major provider of clinical education
- Leading supporter of surgical societies
- Custom instruments business

Broadest, most innovative product offering

- 11-year clinical understanding
- New product pipeline
- Gateway to pediatric market for distributed products and joint product developments



Robust organic growth opportunities

- \$2.5 billion addressable global market
- Limited focused competition
- Focused, experienced distribution
- Instrument set placements drive growth

Attractive growth and margin profile

- Consistent growth since 2011
- 71% gross margins
- History of efficient capital utilization




Financial Review






History of Strong Revenue Growth






Category Revenue Summary






Seasonality Drives Stronger Performance in Summer Months and Holiday Periods

2015



2016






Income Statement Summary

(\$ in Millions)

Year Ended December 31; Nine Months Ended September 30

	2014	2015	2016	9M'16	9M'17
Revenue	\$23.7	\$31.0	\$37.3	\$27.9	\$33.9
<i>Growth %</i>	21%	31%	20%	NA	22%
Gross Profit	\$16.6	\$21.6	\$26.4	\$20.0	\$25.6
<i>Margin %</i>	70%	70%	71%	72%	75%
Operating Expenses	\$23.7	\$28.2	\$32.5	\$22.8	\$27.9
Operating Loss	(\$7.1)	(\$6.6)	(\$6.1)	(\$2.9)	(\$2.3)
Net Loss	(\$9.5)	(\$7.9)	(\$6.6)	(\$2.9)	(\$4.1)





(\$ in Millions)


Nine Months Ended September 30, 2017

Assets		Liabilities	
Cash	\$2.2	Accounts Payable	\$5.1
Accounts Receivable	5.7	Debt	27.5
Inventory	18.4	Accrued Expenses	2.3
PP&E (net)	9.7	All Other Liabilities	3.0
Intangibles	2.2	Paid In Capital	85.2
All Other	0.3	Accumulated Deficit	(82.2)
Total Assets	\$41.1	Total Liabilities / Equity	\$41.1



**Surgeon relationships and
Clinical education**

**Broadest, most innovative
product offering**



**Robust organic growth
opportunities**

**Attractive growth and
margin profile**

